This company is no longer active
0P0 Stock Overview
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Aerie Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.50 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$4.58 |
| Beta | -0.062 |
| 1 Month Change | -5.23% |
| 3 Month Change | 33.03% |
| 1 Year Change | 63.84% |
| 3 Year Change | -14.71% |
| 5 Year Change | -71.88% |
| Change since IPO | 16.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0P0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -2.5% |
| 1Y | 63.8% | -31.3% | -0.4% |
Return vs Industry: 0P0 exceeded the German Pharmaceuticals industry which returned -10.8% over the past year.
Return vs Market: 0P0 exceeded the German Market which returned -21.6% over the past year.
Price Volatility
| 0P0 volatility | |
|---|---|
| 0P0 Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0P0's share price has been volatile over the past 3 months.
Volatility Over Time: 0P0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 376 | Raj Kannan | www.aeriepharma.com |
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases.
Aerie Pharmaceuticals, Inc. Fundamentals Summary
| 0P0 fundamental statistics | |
|---|---|
| Market cap | €735.53m |
| Earnings (TTM) | -€35.68m |
| Revenue (TTM) | €208.81m |
3.5x
P/S Ratio-20.6x
P/E RatioIs 0P0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0P0 income statement (TTM) | |
|---|---|
| Revenue | US$213.94m |
| Cost of Revenue | US$23.52m |
| Gross Profit | US$190.42m |
| Other Expenses | US$226.98m |
| Earnings | -US$36.55m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 89.01% |
| Net Profit Margin | -17.09% |
| Debt/Equity Ratio | -190.6% |
How did 0P0 perform over the long term?
See historical performance and comparison